Development of Clevudine Resistance after Switching from Lamivudine in a Patient with Chronic Hepatitis B / 대한소화기학회지
The Korean Journal of Gastroenterology
;
: 325-328, 2008.
Article
in Korean
| WPRIM
| ID: wpr-204248
ABSTRACT
Clevudine is a nucleoside analog of the unnatural beta-L configuration which has potent antiviral activity against hepatitis B virus (HBV). Clevudine is expected to have similar pattern of resistance profile as lamivudine. However, there was no report on the mutation associated with clevudine resistance in patients with chronic hepatitis B. We report a case of young male patient with chronic hepatitis B who presented with clevudine resistance. The patient had received lamivudine therapy for 5 months with reduced serum HBV DNA levels. Then, lamivudine was switched to clevudine monotherapy. After the 6 months of clevudine therapy, the patient developed virologic breakthrough (>1.0x10(8) copies/mL) as well as biochemical breakthrough, which was associated with the presence of rtM204I plus rtL80I mutant. After switching from clevudine to adefovir, the viral load decreased with biochemical improvement.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Antiviral Agents
/
Arabinofuranosyluracil
/
Phosphorous Acids
/
DNA, Viral
/
Base Sequence
/
Adenine
/
Reverse Transcriptase Inhibitors
/
Lamivudine
/
Hepatitis B, Chronic
/
Amino Acid Substitution
Limits:
Adult
/
Humans
/
Male
Language:
Korean
Journal:
The Korean Journal of Gastroenterology
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS